A possible association between apolipoprotein E polymorphisms and age-related macular degeneration has been investigated numerous times, with conflicting results. A previous analysis pooling results from four studies (Schmidt et al., Ophthalmic Genet 2002;23:209-23) suggested an association, but those investigators did not document allele frequencies, the magnitude of the association, or the possible genetic mode of action. Thus, the authors searched MEDLINE from 1966 to December 2005 for any English-language studies reporting genetic associations. Data and study quality were assessed in duplicate. Pooling was performed while checking for heterogeneity and publication bias. Frequencies of the E 2 and E 4 alleles in Caucasians were approximately 8% and 15%, respectively. Allele-and genotype-based tests of association indicated a risk effect of up to 20% for E 2 and a protective effect of up to 40% for E 4 . E 2 appeared to act in a recessive mode and E 4 in a dominant mode. There appears to be a differential effect of the E 2 and E 4 alleles on the risk of age-related macular degeneration, although the possibility of survivor bias needs to be ruled out more definitively.
Apolipoprotein E (ApoE) is a lipid transport protein that acts as a ligand for the low density lipoprotein receptor, but it is also involved in the repair and maintenance of neuronal cell membranes in the central and peripheral nervous system. The ApoE gene is located at chromosome 19q13.2, and three major forms, originally identified by isoelectric focusing, have been described. These isoforms are defined by amino acid changes at positions 112 and 158: Alleles E 2 , E 3 , and E 4 are defined respectively by cysteine/cysteine, cysteine/ arginine, and arginine/arginine at these two sites (27, 28) .
ApoE is involved in clearance of chylomicrons and very low density lipoproteins from the circulation via specific receptors on liver and peripheral cells. The E 2 form of ApoE has decreased affinity for the receptor, whereas the E 3 and E 4 forms have higher affinity. Mutations in ApoE lead to type III hyperlipoproteinemia, in which there is an increase in triglycerides and cholesterol and premature cardiovascular disease (29) . ApoE has also been linked to Alzheimer's disease. Since 1993, when Saunders et al. (30) reported an increased frequency of the E 4 allele in a small prospective series of Alzheimer's disease patients visiting a memory disorders clinic, multiple studies have confirmed an increased risk of Alzheimer's disease among persons with the E 4 allele.
The genetic association between ApoE and AMD has been investigated multiple times, although the results have been inconsistent (4, 8, (31) (32) (33) (34) (35) (36) . A previous study summarizing results from four groups (8) suggested a protective effect of the E 4 allele and a risk effect of the E 2 allele in comparison with the most common allele, E 3 . We pooled the results of all available population-based studies of the association between ApoE and AMD to ascertain whether there is a genetic effect on AMD susceptibility and, if so, to estimate the magnitude of that effect and the possible genetic mode of action (37, 38) .
MATERIALS AND METHODS

Search strategy
We searched MEDLINE (US National Library of Medicine) for all relevant articles published from January 1966 through November 23, 2005 , using the PubMed search engine. The search strategy was ''macular degeneration'' and ''apolipoprotein E*'' or ''apoE'' or ''APOE'' or ''Apo E.'' Results were limited to English-language papers.
Inclusion criteria
Any human population-based association study, regardless of sample size, was included if it met the following criteria (we use the term ''population-based'' to refer to individual sporadic cases rather than familial cases or familybased study designs (e.g., sibling pairs)):
The investigators determined the association between the ApoE polymorphism and AMD. The alleles and genotypes for this polymorphism were, respectively: E 2 , E 3 , and E 4 ; and E 2 E 2 , E 2 E 3 , E 2 E 4 , E 3 E 3 , E 3 E 4 , and E 4 E 4 . The outcome was AMD and there were at least two comparison groups (e.g., AMD vs. control (non-AMD) groups). For those studies in which AMD was graded (i.e., drusen, pigment abnormalities in retinal pigment epithelium, geographic atrophy, and choroidal neovascularization), these gradings were collapsed into only one AMD group. There were sufficient results for extraction of data (i.e., the number of subjects with each genotype in the AMD and control groups).
We also reviewed the reference lists of the retrieved articles to identify publications on the same topic. Where there were multiple publications from the same study group, the most complete and recent results were used.
Data extraction
Data were extracted independently and in duplicate by two reviewers (T. A. and B. S.) using a standardized data extraction form. Data on covariables such as mean age, gender, and ethnicity were also extracted for each study. Any disagreement was adjudicated by a third author (A. J.).
Quality score assessment
The quality of the studies was independently assessed by two reviewers (B. S. and M. M.) using a quality assessment score developed for genetic association studies (39) . This score was based on both traditional epidemiologic considerations and genetic issues (40) . Total scores ranged from 0 (worst) to 12 (best). Any disagreement was adjudicated by a third author (T. A.).
Statistical analysis
Hardy-Weinberg equilibrium was assessed for each study using the chi-squared test (41) (42) (43) . The summary prevalence of all alleles was estimated and characterized using only the data on controls (39) . Both per-allele analysis and pergenotype analysis were performed.
Per-allele analysis. The association between ApoE polymorphisms and AMD was first determined using the per-allele approach. Allele frequencies were calculated for studies reporting only genotype data.
The Q test for heterogeneity was performed separately for two odds ratios (ORs), that is, E 2 versus E 3 (OR 1 ) and E 4 versus E 3 (OR 2 ). Logistic regression analysis was used to determine the overall gene effect. Bivariate meta-analysis with the maximum likelihood method was used to estimate the summary odds ratios (44) (45) (46) . OR 1 and OR 2 and their 95 percent confidence intervals are reported.
Per-genotype analysis. Once a gene effect was confirmed, per-genotype analysis was used to ascertain the genetic model. Two separate per-genotype analyses-E 2 E 2 , E 2 E 3 , and E 3 E 3 and E 4 E 4 , E 3 E 4 , and E 3 E 3 -were separately explored by assigning E 3 E 3 as the reference group. The genotype effects were estimated using the model-free approach (47) , in which no assumptions about genetic models are required. OR 3 (E 2 E 2 vs. E 3 E 3 ), OR 4 (E 2 E 3 vs. E 3 E 3 ), OR 5 (E 4 E 4 vs. E 3 E 3 ), and OR 6 (E 3 E 4 vs. E 3 E 3 ) were estimated using multivariate meta-analysis with Bayesian methods. The log odds ratios were modeled accounting for both betweenand within-study variation. Two separate lambda values (reflecting the genetic model), which were the ratios of log OR 4 to log OR 3 for k 1 and log OR 6 to log OR 5 for k 2 , were estimated. These parameters capture information about the genetic mode of action, as follows: The model is a recessive model if k ¼ 0, a dominant model if k ¼ 1, a codominant model if k ¼ 0.5, and a homozygous or heterosis model if k > 1 or k < 0.
For per-allele and per-genotype analyses, we took two approaches for handling Hardy-Weinberg disequilibrium. Firstly, we performed sensitivity analyses by including and excluding studies not in Hardy-Weinberg equilibrium. Secondly, we included all studies regardless of Hardy-Weinberg equilibrium and instead adjusted for the degree of disequilibrium using the inbreeding coefficient (F) as described by Trikalinos et al. (48) . Briefly, for per-allele analyses, the variance of the odds ratio was adjusted by 1 þ F (49). Case and control groups were combined for estimation of F using the method described by Ayres and Balding (50) . For genotype analysis, predicted genotype frequencies were estimated in control groups (50), and we used the predicted frequencies instead of the observed frequencies in the summary analysis.
We also performed subgroup analysis in Caucasians. Publication bias was assessed using Egger's test (51, 52) . In addition, we conducted a cumulative meta-analysis to assess whether the gene effect changed over time (52) . All analyses were performed using Stata, version 9.0 (53), except for the per-genotype analysis, which was performed using WinBUGS 1.4.1 (54) . For Bayesian modeling, a vague prior distribution, representing the lack of prior information about parameter values (i.e., log odds ratios and k), was specified using normal-distribution priors for both log odds ratios and k. A ''burn-in'' of 10,000 iterations was carried out for the models, followed by 50,000 iterations for parameter estimates. A p value less than 0.05 was considered statistically significant, except for tests of heterogeneity, where a level of 0.10 was used.
RESULTS
Studies identified
Twenty-eight studies were identified by our search strategies. Eighteen of these studies were not eligible (five were not association studies (55) (56) (57) (58) (59) , five were reviews (3, 8, 15, 26, 60) , three were family-based studies (20, 61, 62) , two were animal studies (63, 64) , one reported only methods (65) , one enrolled diabetic subjects with AMD (66), and one was a duplicate (67)), leaving 10 studies (4, 8, 31-36, 68, 69) for inclusion in this analysis. The 10 studies are described in table 1. Among them, eight studies were carried out in Caucasians and two in Asians. The mean age ranged from 70.9 years to 81.0 years for cases and from 37.0 years to 76.6 years for controls. The percentage of males ranged from 31.6 percent to 63.3 percent.
All studies had case-control designs in which cases and controls were selected from hospitals, except for one study in which cases and controls had been randomly selected from the community (4); in only one of these studies were controls age-and gender-matched. In the two studies by Schmidt et al. (8, 68) , only sporadic cases were used for one (68) , and only two study groups (from the University of California, Los Angeles, and Erasmus University) were used for the other (8) . The quality of studies ranged from 3 to 11, out of a possible score of 12 (see appendix tables 1 and 2). In all studies, investigators used DNA genotyping rather than protein isoforms to determine ApoE status. Genotype-based methods. Table 3 shows the frequencies of the ApoE genotype in case and control groups. We estimated the genotype effects for E 2 E 2 and E 2 E 3 in each study by assigning the E 3 E 3 genotype as the reference group (table 4) . Cells with a zero count had 0.5 added. Two Asian studies (34, 36) did not have E 2 E 2 genotypes in either case groups or control groups, and thus results for these studies
could not be summarized. The summary odds ratios for the E 2 E 2 and E 2 E 3 genotypes were 1.05 (95 percent CI: 0.52, 2.20) and 1.22 (95 percent CI: 0.96, 1.61), respectively. These point estimates can be interpreted as meaning that persons with the E 2 E 2 and E 2 E 3 genotypes had 5 percent and 22 percent higher risks of developing AMD than persons with the E 3 E 3 genotype, although these effects did not reach statistical significance. The estimated k was 0.27 (95 percent CI: -3.98, 4.93), which suggests a largely recessive mode of action, although the confidence interval was wide.
There was no evidence of publication bias due to the size of the study (Egger's test: for OR 3 and OR 4 , p ¼ 0.78 and p ¼ 0.85, respectively). Cumulative meta-analysis was performed for OR 3 and OR 4 . It showed that the summary OR 3 was a bit different in the first two studies (4, 35) and was not much changed, whereas the cumulative OR 4 did not change much over time ( figure 1 ). Sensitivity analysis conducted by There was no publication bias due to study size (for OR 5 and OR 6 , p ¼ 0.10 and p ¼ 0.92, respectively). The cumulative meta-analysis for OR 5 and OR 6 (figure 2) showed that the summary OR 5 did not change over time, whereas the Genotype
Klaver ( 
DISCUSSION
Our study found that the prevalences of ApoE alleles E 2 and E 4 were largely similar between Caucasians and Asians. Assuming a per-allele model, which allowed us to conduct one overall test of association and avoid multiple comparisons, we found that ApoE gene polymorphisms were indeed associated with AMD, with the E 4 allele appearing to be protective and E 2 appearing to be a risk allele. Over half of the studies included (5/9) were of good quality, with a quality score of 10 or above out of 12. Exploring this association in more detail allowed us to estimate the magnitude of the association and the possible genetic mode of action. Results for the E 2 allele did not reach statistical significance, but point estimates appeared to indicate up to a 20 percent increase in risk of AMD and suggested a recessive model. Results for the E 4 allele did reach statistical significance and indicated that E 4 might act dominantly, with the presence of at least one E 4 allele providing up to a 38 percent reduction in the risk of AMD.
These results are strengthened by the facts that there was no evidence of heterogeneity and that including the one study not in Hardy-Weinberg equilibrium gave us similar results. Egger's test evaluates whether small studies produce different results than larger studies. If so, publication bias is a possibility. In this meta-analysis, the result of Egger's test was not significant, but with only 10 studies we had limited power to detect such an effect. The indications of a risk Baird (32) Zareparsi (69) Schultz (31) Schmidt (8) Schmidt (68) Klaver (4) Souied ( effect of E 2 and a protective effect of E 4 are consistent with results from an earlier, smaller pooling study (8) . In addition, the two main types of AMD may have different etiologies (9) and hence may have different genetic susceptibilities. However, there was insufficient information provided in the papers to meta-analyze these two types of AMD separately. Combining both as a single AMD outcome would introduce measurement error in the outcome factor and could lead to a bias towards the null. This bias makes our significant results more robust. Nevertheless, there are two major concerns. Firstly, this E 4 effect is the opposite of that found for cardiovascular disease; that is, E 4 is associated with increased mortality and decreased longevity. Hence, one might expect that any survivor bias would ''deplete'' the E 4 allele among persons old enough to develop AMD, and this decreased odds ratio might therefore be spurious. This remains a possibility because, although most studies had similar age distributions in cases and controls, cases had older mean ages than controls. In defense of our results is the finding that all studies but one were in Hardy-Weinberg equilibrium, and the one not in Hardy-Weinberg equilibrium was excluded from the summary analysis. However, it is puzzling that the risk allele for cardiovascular disease should have a beneficial effect for AMD if the mechanism is still related to cholesterol metabolism. This could indicate a type I (i.e., false-positive) error, although there are many examples of pleiotropy in biology (i.e., multiple functions for the same protein or gene), and it is difficult to predict the direction of a genetic effect given the biology. Secondly, the studies included in this meta-analysis were all small or medium-sized casecontrol studies. There is some evidence that smaller studies tend to overstate genetic effects in comparison with larger studies (70) .
Despite these potential problems, our results are statistically robust and point to some interesting directions for future research. In particular, this review indicates the need for confirmation of these results in a large-scale, longterm longitudinal study in which survivor bias might be detected. Baird (32) Zareparsi (69) Schultz (31) Schmidt (8) Schmidt (68) Klaver (4) Souied (35) FIGURE 2. Odds ratios (ORs) OR 5 (E 4 E 4 vs. E 3 E 3 ) and OR 6 (E 3 E 4 vs. E 3 E 3 ) in a cumulative meta-analysis of apolipoprotein E polymorphisms among patients with age-related macular degeneration and controls. Horizontal bars, 95% confidence interval.
